Loading clinical trials...

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | Clinical Trials | Clareo Health

UNKNOWNPHASE2

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

A Randomized, Open-label, Phase II Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

NCT05007145•Fujian Cancer Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable thoracic esophageal squamous cell carcinoma.

Detailed Description

This is a randomized, open-label, phase II study of PD-1 inhibitor combined With neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy in subjects With resectable locally advanced thoracic esophageal squamous cell carcinoma. The patients will be divided into two groups(1:1). In the treatment group, PD-1 inhibitor ,albumin-bound paclitaxel and cisplatin will be given every 3 weeks for 2-4 cycles as neoadjuvant therapy. In the control gourp, albumin-bound paclitaxel and cisplatin will be given every 3 weeks for 2 cycles as neoadjuvant therapy.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Volunteered to participate in the study, signed the informed consent form;
•2. Histologically or cytological confirmed esophageal squamous cell carcinoma;
•3. Patients with resectable disease of primary tumor in thoracic esophagus (cT1b-4aN1-3M0, cT3-4aN0M0) evaluated by CT/MRI/EUS;
•4. Expected R0 resection;
•5. Aged 18-75 years, male or female;
•6. ECOG PS 0-1;
•7. Without prior treatments including surgery, chemotherapy, radiotherapy, and targeting treatment for esophageal cancer;
•8. Surgery is planned after neoadjuvant treatment;
•9. Without any contraindication of operation;
•10. Adequate organ function as follows: 1) Routine blood test: Leukocytes \>=3.0x10\^9/L; Absolute neutrophil count \>=1.0x10\^9/L; Platelet \>=80x10\^9/L; Hemoglobin \>=90 g/L; 2) Blood biochemical test: Total bilirubin \<=1.5 ULN; ALT \<=2.5 ULN; AST \<=2.5 ULN; Serum creatinine \<=1.5 ULN or creatinine clearance rate \>=50 mL/min (Cocheroft-Gault); 3) Coagulation function test: INR \<=1.5 ULN; APTT \<=1.5 ULN;
+2 more criteria

Exclusion Criteria

•1. The tumor invades the adjacent organs of the esophageal lesion (aorta or trachea);
•2. Patients with supraclavicular lymph node metastasis;
•3. Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage;
•4. Poor nutritional status, BMI \< 18.5 Kg/m2; If corrected after nutritional support before randomization, enrollment can be further considered after evaluation by the principal investigator;
•5. Has a history of allergy to monoclonal antibody, any component of PD-1 Inhibitor, paclitaxel, cisplatin or other platinum drugs;
•6. Has received or is receiving any of the following treatments: A)any anti-tumor radiation, chemotherapy or other treatment drugs; B) Immunosuppressive drugs or whole-body hormone drugs are being used for immunosuppressive purposes within 2 weeks prior to the first use of the study drug (dose \> 10mg/ day prednisone or equivalent dose);Inhalation or topical use of steroids and 10 mg/ day prednisone or equivalent dose of adrenocortical hormone replacement is permitted in the absence of active autoimmune disease; C) Received attenuated vaccine within 4 weeks before the first use of the study drug; D) Major surgery or severe trauma within 4 weeks prior to the first use of the study drug;
•7. History of any active autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypohysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (may be considered after hormone replacement therapy);Patients with psoriasis or childhood asthma/allergy who have been in complete remission and do not need any intervention as adults may be considered for inclusion, but patients requiring medical intervention with bronchodilators may not be included;
•8. History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency disease, or history of organ transplantation or allogeneic bone marrow transplantation;
•9. Present of poorly controlled cardiac symptoms or disease, including but not limited to: (1) heart failure with NYHA class II or above (2) unstable angina, （3）myocardial infarction occurred within 1 year (4) clinical significance supraventricular or ventricular arrhythmias without clinical intervention or poorly controlled after clinical intervention;
•10. Severe infection (CTCAE \> 2) occurred within 4 weeks prior to the first use of the study drug, such as severe pneumonia, bacteremia, infection complications requiring hospitalization, etc.;Baseline chest imaging indicated active pulmonary inflammation, infection signs and symptoms within 14 days prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment, except prophylactic antibiotic usage;
+6 more criteria

Locations (6)

Fujian Cancer Hospital

Fuzhou, Fujian, China

the Second Hospital of Longyan

Longyan, Fujian, China

the First Hospital of Putian City

Putian, Fujian, China

Fujian Medical University 2nd Affiliated Hospital

Quanzhou, Fujian, China

Quanzhou First Hospital

Quanzhou, Fujian, China

the First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

Key Dates

Start Date

August 15, 2021

Primary Completion Date

August 31, 2023

Completion Date

August 31, 2023

Last Updated

December 21, 2021

Enrollment

ESTIMATED participants

Conditions

Esophageal NeoplasmsEsophageal Squamous Cell Carcinoma

Interventions

PD-1 inhibitor

DRUG

Albumin-Bound Paclitaxel

DRUG

Cisplatin

DRUG

Radiation

RADIATION

Contacts

Shuoyan Liu

CONTACT

+86 13805088816 shuoyanliu2010@163.com

Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC

NCT07403136

Esophageal Squamous Cell Carcinoma

View study

RECRUITINGPHASE2

Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study

NCT07437898

Esophageal Squamous Cell Carcinoma

View study

RECRUITING

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

NCT04290806

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 21, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Inclusion Criteria

Exclusion Criteria

Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC

Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer